Strategic Acquisition Entry Imbio was acquired by 4D Medical in December 2023 for up to $45 million, signaling market validation and potential channels to leverage for cross-sell or integration opportunities with CT analytics capabilities and AI-driven lung assessment.

FDA Cleared Advantage Lung Density Analysis is FDA Cleared and CE Mark Certified, offering a credible regulatory edge that can reassure potential hospital systems and radiology networks about adoption risk and reimbursement alignment.

Automation Speed Fully automated results delivered in minutes present a strong value proposition for high-volume imaging centers and health systems seeking workflow efficiency gains and faster clinical decision support.

Strategic Partnerships A track record of partnerships with Medical-Note, Heart&Lung Health, Spesana, Olympus America and others demonstrates a ready-made ecosystem for distribution, integration, and co-sell motions into diverse markets including UK and molecular diagnostics spaces.

Growth Opportunities Revenue is currently in the sub-1M range with a lean team, suggesting upside through enterprise deals, expanded reseller networks, and strategic alliances with larger health-tech platforms and AI-driven imaging solutions.